Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876255 | 0.88 | HTR1A (0.46) | — | |
| SCHEMBL4874631 | 0.85 | DRD2 (0.42) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4871728 | 0.82 | DRD2 (0.42) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4871732 | 0.81 | DRD2 (0.40) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4876727 | 0.79 | DRD2 (0.40) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4874991 | 0.77 | HSD17B10 (0.38) | DRD2DRD3HTR2ADRD4TP53 | |
| SCHEMBL4876083 | 0.77 | DRD2 (0.42) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4871786 | 0.76 | KMT2A (0.50) | DRD2DRD3TP53ALOX15TSHR | |
| SCHEMBL4871708 | 0.75 | MEN1 (0.38) | DRD2DRD3HTR2ADRD4DRD1 | |
| SCHEMBL4875187 | 0.75 | DRD2 (0.38) | DRD2DRD3HTR2ADRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | claimed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | claimed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | claimed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | claimed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | claimed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | disclosed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | disclosed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | DRD2 20/4885DRD3 27/4885HTR2A 41/4885 |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR2C | DRD2 23/4885DRD3 29/4885HTR2A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.